Skip to main content

Table 1 Summary of pharmacokinetic characteristics of rivaroxaban at steady state based on phase II data

From: Laboratory assessment of rivaroxaban: a review

Parameter

Rivaroxaban dose

 

2.5 mg bid*

2.5 mg bid#

5 mg bid*

10 mg bid*

20 mg bid*

30 mg bid‡

AUC (μg.h/l)

300

328

464

974

1764

6500

Cmax (μg/l)

53

40

86

180

299

400

Ctrough (μg/l)

8

14

11

38

68

160

  1. *Data are mean values from an analysis of the ODIXa-HIP2 study [17]. #Data are median values from an analysis of the ATLAS ACS TIMI 46 study (subset of patients aged <50 years) [18]. ‡Data are mean values from an analysis of the ODIXa-DVT study [19].
  2. Abbreviations: AUC area under the concentration–time curve, bid twice daily, C max maximum plasma concentration, C trough minimum plasma concentration.
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us